CELZ substantially increased its outstanding share count from 1.7M to 3.7M shares while reducing share buyback activity and experiencing declining revenue performance.
The more than doubling of outstanding shares suggests significant dilution for existing shareholders, likely from equity financing to fund operations. Combined with reduced revenue and continued negative operating cash flow, this indicates the company is burning through capital to sustain its biotechnology development activities.
The company's balance sheet strengthened with current assets growing to $7.4M and stockholders' equity increasing to $7.5M, while liabilities declined modestly to $285K. However, operational performance weakened as revenue declined to $6K, gross profit fell to $4K, and SG&A expenses increased to $3.8M. The significant reduction in share buybacks from $175K to $10K, combined with the doubling of shares outstanding, suggests the company prioritized capital preservation while potentially raising funds through equity issuance.
Buyback activity reduced 94.3% — capital being redeployed elsewhere or cash conservation underway.
Revenue declined 45.5% — significant demand weakness or market share loss warrants investigation.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Current assets grew 20.6% — improving short-term liquidity or inventory/receivables build.
Equity base grew 18.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 17.1% — expansion through organic growth, acquisitions, or capital deployment.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Liabilities reduced 13.1% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →